

AN 2003-300573 [29] WPIX

DNC C2003-078270

TI Pharmaceutical composition e.g. for breast cancer comprises gonadotrophin releasing hormone agonist and selective estrogen receptor modulator.

DC B05

IN FURUYA, S; KUSAKA, M

PA (TAKE) TAKEDA CHEM IND LTD

CYC 100

PI WO 2003015820 A1 20030227 (200329)* JA 73<--

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU

MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK

DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO

RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

JP 2003137814 A 20030514 (200340) 25

EP 1424080 A1 20040602 (200436) EN

R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC

MK NL PT RO SE SI SK TR

AU 2002325516 A1 20030303 (200452)

ADT WO 2003015820 A1 WO 2002-JP8130 20020808; JP 2003137814 A JP 2002-231922

20020808; EP 1424080 A1 EP 2002-758814 20020808, WO 2002-JP8130 20020808;

AU 2002325516 A1 AU 2002-325516 20020808

FDT EP 1424080 A1 Based on WO 2003015820; AU 2002325516 A1 Based on WO 2003015820

PRAI JP 2001-244616 20010810

AN 2003-300573 [29] WPIX

AB WO2003015820 A UPAB: 20030505

NOVELTY - Pharmaceutical composition for breast cancer, endometriosis, myometrium tumor, Alzheimer's disease, circulatory system disorders, menopausal disorders, irregular periods, cancer metastasis, premenstrual syndrome, muscular distress or osteopathies due to calcium/phosphorus imbalance comprises a gonadotrophin releasing hormone agonist and a selective estrogen receptor modulator.

DETAILED DESCRIPTION - Pharmaceutical composition for breast cancer, endometriosis, myometrium tumor, Alzheimer's disease, circulatory system disorders, menopausal disorders, irregular periods, cancer metastasis, premenstrual syndrome, muscular distress or osteopathies due to calcium/phosphorus imbalance comprises a gonadotrophin releasing hormone agonist (GnRH) and a selective estrogen receptor modulator (SERM). INDEPENDENT CLAIMS are also included for:

- (1) the use of a GnRH and a SERM in add-back therapy;
- (2) pharmaceutical composition for prostatomegally or prostate cancer comprising GnRH and a selective androgen receptor modulator (SARM);
- (3) agent for treating and preventing prostatomegally or prostate cancer or breast cancer or their reoccurrence or metastasis comprising GnRH and a sex hormone synthesis inhibitor, lyase inhibitor, receptor-type tyrosine kinase inhibitor, cytokine/chemokine inhibitor or endothelin receptor antagonist;
- (4) agent for treating and preventing prostatomegally, breast cancer or prostate cancer or their reoccurrence or metastasis, menopausal disorders or osteopathies due to calcium.phosphorus imbalance comprising a GnRH and a bone metabolism regulator; and
- (5) agent for treating and preventing breast cancer or prostate cancer or their reoccurrence or metastasis, myometrium tumor, endometriosis or prostatomegally comprising a GnRH and an immunotherapy drug.

ACTIVITY - Cytostatic; Gynecological; Nootropic; Neuroprotective; Cardiovascular-Gen.; Endocrine-Gen.; Muscular-Gen.; Osteopathic.

No biological activity data is given.

MECHANISM OF ACTION - Gonadolibrin-Agonist; Estrogen-Agonist; Estrogen-Antagonist; Androgen-Agonist; Androgen-Antagonist; Tyrosine-Kinase-Inhibitor; Cytokine-Antagonist; Chemokine-Antagonist; Endothelin-Antagonist.

USE - As gonadotrophin releasing hormone agonists used in combination with selective estrogen receptor modulators, selective androgen receptor modulators, sex hormone synthesis inhibitors, lyase inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, immunotherapy drugs, cytokine/chemokine inhibitors or endothelin receptor antagonists for treating and preventing endometriosis, myometrium tumor, Alzheimer's disease, circulatory system disorders, menopausal disorders, irregular periods, cancer metastasis, premenstrual syndrome, muscular distress, osteopathies due to calcium.phosphorus imbalance, prostatomegally or prostate cancer or breast cancer or their reoccurrence or metastasis.

ADVANTAGE - Combination enhances quality of life by enhancing gonadotrophin releasing hormone agonist activity and/or reducing side effects.
Dwg.0/0